TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03988452

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Darunavir
Description: Antiretroviral therapy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Darunavir
Description: Antiretroviral therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ritonavir
Description: Antiretroviral therapy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ritonavir
Description: Antiretroviral therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dolutegravir
Description: Antiretroviral therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dolutegravir
Description: Antiretroviral therapy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zidovudine
Description: Antiretroviral therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zidovudine
Description: Antiretroviral therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenofovir
Description: Antiretroviral therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenofovir
Description: Antiretroviral therapy
Study: NCT01750307

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Experimental fatty acid supplementation
Description: 4 x capsules per day. Daily dose: 1584mg EFA
Study: NCT03988452

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lamivudine
Description: Antiretroviral therapy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lamivudine
Description: Antiretroviral therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lamivudine
Description: Antiretroviral therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lamivudine
Description: Antiretroviral therapy
Study: NCT02759341

Intervention type: OTHER
Group type: OTHER
Intervention: Manual for the Assessment and Documentation of Psychopathology (AMDP 8)
Study: NCT01750307

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo comparator: MCT oil softgel
Description: 4 x capsules per day. Medium chain triglyceride pill manufactured to mimic essential fatty acid pill
Study: NCT04492631

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Streptococcus salivarius DB-B5
Description: Sachets containing Streptococcus salivarius DB-B5 will be dissolved in water and consumed by the participants (n=30) once daily for 4 weeks. The participants will consume 10 billion colony forming units (CFU) per day.
Study: NCT01406847

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Spinal Manipulation
Description: High velocity low amplitude joint-biased intervention

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Spinal Mobilization
Description: Low velocity, large amplitude oscillating joint biased technique

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Static Touch
Description: The investigators maintains hand contact with both hands over the lumbar area of the participant
Study: NCT01972880

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP1941
Description: Oral

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ASP1941
Description: Oral
Study: NCT03902743

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Anticipatory Care Plan group
Description: The Anticipatory Care Plan will be delivered by a trained nurse. At the initial visit, the nurse will conduct a hollistic assessment using the EasyCare Assessment Tool. Following this visit, the nurse will draft a strucutred summary report of the home visit to include patient goals, preferences for care, identified problems and action list. The nurse will then consult with a pharmacist to identify any potential inappropriate prescribing. The nurse will then meet with the participants GP and review and provide feedback. The nurse will then re visit participants and discuss the report and agree a support plan and actions for follow up.
Study: NCT05162950

Intervention type: DIAGNOSTIC_TEST
Intervention: physical exercise as a standardized high intensity exercise test
Description: High intensity exercise test, cycling, performed at the Karolinska University Hospital

Intervention type: DIAGNOSTIC_TEST
Intervention: physical exercise as a standardized high intensity exercise test
Description: High intensity exercise test, cycling, performed at the Karolinska University Hospital

Intervention type: DIAGNOSTIC_TEST
Intervention: physical exercise as a standardized high intensity exercise test
Description: High intensity exercise test, cycling, performed at the Karolinska University Hospital

Intervention type: DIAGNOSTIC_TEST
Intervention: physical exercise as a standardized high intensity exercise test
Description: High intensity exercise test, cycling, performed at the Karolinska University Hospital

Intervention type: DIAGNOSTIC_TEST
Intervention: physical exercise as a standardized high intensity exercise test
Description: High intensity exercise test, cycling, performed at the Karolinska University Hospital

Intervention type: BEHAVIORAL
Intervention: Stress vulnerability
Description: Web based survey of validated psychological questionnaires measuring fatigue (MFS), exhaustion disorder (KEDS), anxiety (LSAS-SR, HADS), depression (HADS), and Karolinska sleep questionnaire

Intervention type: BEHAVIORAL
Intervention: Stress vulnerability
Description: Web based survey of validated psychological questionnaires measuring fatigue (MFS), exhaustion disorder (KEDS), anxiety (LSAS-SR, HADS), depression (HADS), and Karolinska sleep questionnaire

Intervention type: BEHAVIORAL
Intervention: Stress vulnerability
Description: Web based survey of validated psychological questionnaires measuring fatigue (MFS), exhaustion disorder (KEDS), anxiety (LSAS-SR, HADS), depression (HADS), and Karolinska sleep questionnaire

Intervention type: BEHAVIORAL
Intervention: Stress vulnerability
Description: Web based survey of validated psychological questionnaires measuring fatigue (MFS), exhaustion disorder (KEDS), anxiety (LSAS-SR, HADS), depression (HADS), and Karolinska sleep questionnaire

Intervention type: BEHAVIORAL
Intervention: Stress vulnerability
Description: Web based survey of validated psychological questionnaires measuring fatigue (MFS), exhaustion disorder (KEDS), anxiety (LSAS-SR, HADS), depression (HADS), and Karolinska sleep questionnaire
Study: NCT02759341

Intervention type: OTHER
Group type: OTHER
Intervention: Manual for the Assessment and Documentation of Psychopathology (AMDP 8)

Intervention type: OTHER
Group type: OTHER
Intervention: Manual for the Assessment and Documentation of Psychopathology (AMDP 8)
Study: NCT04157985

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Continue PD-1/PD-L1 Inhibitors treatment
Description: Continued treatment with PD-1/PD-L1-1 inhibitor
Study: NCT02759341

Intervention type: OTHER
Group type: OTHER
Intervention: Million Clinical Multiaxial Inventory 3 (MCMI-III)

Intervention type: OTHER
Group type: OTHER
Intervention: Million Clinical Multiaxial Inventory 3 (MCMI-III)
Study: NCT04492631

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sachets containing a placebo (probiotic carrier) will be dissolved in water and consumed by the participants (n=30) once daily for 4 weeks.
Study: NCT02759341

Intervention type: OTHER
Group type: OTHER
Intervention: Million Clinical Multiaxial Inventory 3 (MCMI-III)
Study: NCT04157985

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Discontinue PD-1/PD-L1-1 inhibitor
Description: Discontinued treatment with PD-1/PD-L1-1 inhibitor
Study: NCT05477342

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Board Game
Description: The BG group that will play the game were divided into four groups with five or six participants in each group. (GP (Game Player) GP1- GP 2- GP 3- GP 4.
Study: NCT02753413

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RSV vaccine GSK3003891A
Description: Single dose administered intramuscularly at Day 0 in the deltoid region of the non-dominant arm.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Boostrix
Description: Single dose administered intramuscularly at Day 0 in the deltoid region of the non-dominant arm.
Study: NCT04464421

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Contingency Management (CM)
Description: Participants were able to draw a gift card from a virtual fishbowl when their urine toxicology results are positive for buprenorphine metabolites. Gift card values were $25, $50, or $100.
Study: NCT05477342

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tobacco Cesseation Education
Description: The TCE group were divided three group that E1 (Precontemplation) -E2 (Contemplation)-E3 (Preparation) according to the thinking stages scale.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Combined İntervention
Description: The CI group was divided into five groups for play that will play the game were divided into four groups with five or six participants in each group. (GP (Game Player)GP 5- GP 6- GP 7- GP 8- GP 9).~The CI group was divided into three groups for education that E4 (Precontemplation) -E5 (Contemplation)-E6 (Preparation) according to the thinking stages scale.
Study: NCT05682820

Intervention type: DIAGNOSTIC_TEST
Intervention: Measurements on knee MRI performed during routine clinical practice
Description: Patients after knee injury are often advised to undergo knee MRI for diagnosis. Measurements on knee MRI performed during routine clinical practice will be made.

Intervention type: DIAGNOSTIC_TEST
Intervention: Measurements on knee MRI performed during routine clinical practice
Description: Patients after knee injury are often advised to undergo knee MRI for diagnosis. Measurements on knee MRI performed during routine clinical practice will be made.
Study: NCT02691156

Intervention type: DIAGNOSTIC_TEST
Intervention: Bilirubin Binding Capacity
Description: Research laboratory assay of bilirubin binding capacity

Intervention type: DIAGNOSTIC_TEST
Intervention: End-tidal Carbon Monoxide
Description: Noninvasive bedside test to measure exhaled end-tidal carbon monoxide levels for the detection of hemolysis

Intervention type: DIAGNOSTIC_TEST
Intervention: Carboxyhemoglobin
Description: Laboratory assay of carboxyhemoglobin levels for the detection of hemolysis
Study: NCT04622592

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Instramuscular vaccine
Description: On Day 0, a single injection of the assigned dose of the vaccine into the deltoid region of the arm

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Instramuscular vaccine
Description: On Day 0, a single injection of the assigned dose of the vaccine into the deltoid region of the arm
Study: NCT04464421

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief Motivational Intervention + Substance Free Activities Session + Mindfulness-Based Adherence Promotion (BSM)
Description: Participants had one-on-one sessions with a behavioral interventionist to discuss their goals regarding treatment, how to reach these goals, the importance of substance-free activities, and mindfulness skills.
Study: NCT01664871

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DIammine SIlver Fluoride
Description: Concentrations of Silver and Fluoride in the DSF used for study were 24.9% and 5.5%, respectively Average total weight (calculated volume) of Diammine Silver Fluoride applied was 7.57 mg (6.04 µL), corresponding to a mean application of 0.33 mg Fluoride based on the lot analysis. The mean total amount of Silver applied to the 3 teeth was 1.50 mg.
Study: NCT02338245

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASLAN001
Description: ASLAN001 400mg BID

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lapatinib
Description: Lapatinib 1250mg QD
Study: NCT04622592

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Instramuscular vaccine
Description: On Day 0, a single injection of the assigned dose of the vaccine into the deltoid region of the arm
Study: NCT02338245

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Capecitabine 1000mg/kg BID days 1-14 of a 21-day cycle

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capecitabine
Description: Capecitabine 1000mg/kg BID days 1-14 of a 21-day cycle
Study: NCT02874118

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Fried scale for frailty assessement
Study: NCT00785863

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo IV before placebo infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Remifentanil
Description: placebo IV and remifentanil infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketorolac and remifentanil
Description: Ketorolac IV and remifentanil infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Parecoxib and remifentanil
Description: Parecoxib IV and remifentanil infusion
Study: NCT01499134

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nebivolol
Description: Study medication will initially be dispensed as one capsule daily and the dose will be titrated at the study visits. Nebivolol is approved for hypertension treatment at a dose of 5-40 mg daily. Based on the study titration schedule, the maximum doses used will be 20 mg of nebivolol (each maximum dose being contained in 4 capsules for daily dosing).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metoprolol succinate
Description: Study medication will initially be dispensed as one capsule daily and the dose will be titrated at study visits. Metoprolol succinate at 25-400 mg daily. Based on the study titration schedule, the maximum dose used will be 200 mg of metoprolol succinate (each maximum dose being contained in 4 capsules for daily dosing).
Study: NCT00542113

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: DvtProgram ENERGY
Description: 11 - weekly or biweekly newsletters about diabetes and its prevention and family challenges sent home with children

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: DvtProgram ENERGY
Description: 6 - weekly or biweekly newsletters about diabetes and its prevention and family challenges sent home with children

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: DvtProgramENERGY
Description: Children participating in Program ENERGY but no newsletters or family challenges sent home to parents
Study: NCT05790408

Intervention type: DEVICE
Group type: OTHER
Intervention: Digital microscope integrated with intraoperative OCT (Zeiss Artevo 800, Carl Zeiss Meditec AG)
Description: The Zeiss Artevo digital microscope integrated with iOCT (Zeiss Artevo 800, Carl Zeiss Meditec AG) is a commercially available, FDA approved device that can be utilized to visualize and evaluate the morphology of the trabeculectomy bleb during transconjunctival needle revision of trabeculectomy bleb.

Intervention type: DEVICE
Group type: OTHER
Intervention: Spectralis Anterior-segment OCT (AS-OCT) (Heidelberg Engineering)
Description: The Spectralis Anterior-segment OCT (AS-OCT) is a commercially available, FDA approved device that can be utilized to visualize and evaluate the morphology of the trabeculectomy bleb in the office.
Study: NCT03996746

Intervention type: DIAGNOSTIC_TEST
Intervention: No intervention
Description: No intervention

Intervention type: DIAGNOSTIC_TEST
Intervention: No intervention
Description: No intervention
Study: NCT03921450

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 1 Hz rTMS
Description: 1 Hz stimulation at 110% of resting motor threshold over supplementary motor area

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: iTBS
Description: 50 Hz theta burst stimulation at 80% of resting motor threshold over supplementary motor area

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 Hz stimulation with the placebo TMS coil without any magnetic emission
Study: NCT06552676

Intervention type: PROCEDURE
Intervention: Percutaneous tracheostomy
Description: Percutaneous tracheostomy is a widely used technique in intensive care. It involves creating a passage between the tracheal lumen and the outside, through which a cannula is placed.
Study: NCT04622592

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Instramuscular vaccine
Description: On Day 0, a single injection of the assigned dose of the vaccine into the deltoid region of the arm

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Instramuscular vaccine
Description: On Day 0, a single injection of the assigned dose of the vaccine into the deltoid region of the arm

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Instramuscular vaccine
Description: On Day 0, a single injection of the assigned dose of the vaccine into the deltoid region of the arm

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Instramuscular vaccine
Description: On Day 0, a single injection of the assigned dose of the vaccine into the deltoid region of the arm

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Instramuscular vaccine
Description: On Day 0, a single injection of the assigned dose of the vaccine into the deltoid region of the arm
Study: NCT01067807

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 25 mg Proellex
Description: 25 mg - given as one 25 mg capsule (252 mg of Gelucire and 88 mg of PEG400, original formulation) \[Original\], single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 25 mg Proellex
Description: 25 mg - given as one 25 mg capsule (coated with microcrystalline cellulose, new formulation) (coated), single dose
Study: NCT00530517

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intraject Sumatriptan
Description: needle-free, single use, disposable, subcutaneous delivery system pre-filled with 6mg Sumatriptan
Study: NCT00680342

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Silymarin
Description: 700mg dose (5 pills, three times daily) for 24-week treatment period

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Silymarin
Description: 420mg dose (5 pills, three times daily) for 24-week treatment period

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo (5 pills, three times daily) for 24-week treatment period
Study: NCT02729701

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Duavee
Description: Once daily tablet of Duavee (Bazedoxifene (20 mg) plus conjugated estrogen (0.45 mg))
Study: NCT03329144

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioural Therapy
Description: The transdiagnostic CBT-based curriculum is based on the extensive clinical experience of the research team with young women and those struggling with perinatal mental disorders. The team also has significant expertise delivering CBT for depression and anxiety (including perinatal variants) in groups. The manual was developed by the research team and is based on the state-of-the-art in resilience and CBT interventions in adolescents and young adults (e.g., the Penn Resiliency Program (60), Treatment for Adolescent Depression Study (61)). After it was developed, it was subjected to further scrutiny by public health nurses and STRIVE staff, who have extensive experience working with young mothers.
Study: NCT01771666

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SPY Elite Imaging
Description: A camera that is directed into the axillary cavity to try to capture an image of the tumor site labeled with Indocyanine green before and after excising sentinel nodes

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indocyanine Green
Description: started at 1mg /mL~If fluorescence is not detected with this dose, then it will be increased by 50%.
Study: NCT02860533

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: cuff device
Description: Measurement of blood pressure during stress testing with cuff device

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: iphone
Description: Measurement of blood pressure during stress testing with iPhone
Study: NCT02759341

Intervention type: OTHER
Group type: OTHER
Intervention: State-Trait Anxiety Inventory form Y (STAI-Y)

Intervention type: OTHER
Group type: OTHER
Intervention: State-Trait Anxiety Inventory form Y (STAI-Y)

Intervention type: OTHER
Group type: OTHER
Intervention: State-Trait Anxiety Inventory form Y (STAI-Y)

Intervention type: OTHER
Group type: OTHER
Intervention: SF-36 Health-Related Quality of Life

Intervention type: OTHER
Group type: OTHER
Intervention: SF-36 Health-Related Quality of Life

Intervention type: OTHER
Group type: OTHER
Intervention: SF-36 Health-Related Quality of Life

Intervention type: OTHER
Group type: OTHER
Intervention: Blood oxygenation level dependent- functional Magnetic Resonance Imaging (BOLD-fMRI)

Intervention type: OTHER
Group type: OTHER
Intervention: Blood oxygenation level dependent- functional Magnetic Resonance Imaging (BOLD-fMRI)

Intervention type: OTHER
Group type: OTHER
Intervention: Blood oxygenation level dependent- functional Magnetic Resonance Imaging (BOLD-fMRI)
Study: NCT01695096

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: The Embryos will be cultured on a humidity free incubator
Description: We will set the humidity level to 0.0% in the IVF incubator that will be used for culturing the Human embryos after ICSI procedure and we will monitor the outcome embryologically and clinically and record the results.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: The Embryos will be cultured on a >95% humidity incubator
Description: We will set the humidity level to 95% in the IVF incubator that will be used for culturing the Human embryos after ICSI procedure and we will monitor the outcome embryologically and clinically and record the results.
Study: NCT03135899

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 443651
Description: Three doses, each 12 hours apart

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Three doses, each 12 hours apart
Study: NCT00946491

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Haloperidol 10 mg Tablets (Cord Laboratories)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Haldol 10 mg Tablets (McNeil Pharmaceuticals)
Study: NCT01877460

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dietary intervention
Description: All arms were given to all participants, in a randomized order, to be consumed within 10 min after 12-h overnight fasting.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dietary intervention
Description: All arms were given to all participants, in a randomized order, to be consumed within 10 min after 12-h overnight fasting.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dietary intervention
Description: All arms were given to all participants, in a randomized order, to be consumed within 10 min after 12-h overnight fasting.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dietary intervention
Description: All arms were given to all participants, in a randomized order, to be consumed within 10 min after 12-h overnight fasting.